Insider · CIK 0001884274
Damien Lamendola
Files at MRAI (Marpai, Inc.). First filing Nov 21, 2023, latest Oct 2, 2025.
In brief
Damien Lamendola files SEC Form 4 as CEO, director and 10% owner at MRAI (Marpai, Inc.). Since Nov 21, 2023, Damien Lamendola has reported 6 open-market buys worth $2.2M and 0 open-market sells worth $0, the latest filed on Oct 2, 2025.
After Damien Lamendola's past buys, the stock trailed the S&P 500 by a median 67.8% over six months (n = 4), and 0% of those buys were ahead of the index at six months. InsiderTell labels that a negative record.
The newest scored trade: bought $200k of MRAI on Sep 30, 2025, filed Oct 2, 2025, scored 46 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MRAI: Marpai, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | MRAIbuy Marpai, Inc. | $200k 147,058 shares | +2% | +186% from low-17% from high | |
| 61Notable | MRAIbuy Marpai, Inc. | $950k 896,903 shares | +17% | +159% from low-25% from high | |
| 53Moderate | MRAIbuy Marpai, Inc. | $400k 371,470 shares | +7% | +179% from low-19% from high | |
| 39Weak | MRAIbuy Marpai, Inc. | $100k 86,805 shares | +2% | +188% from low-16% from high | |
| 53Moderate | Marpai, Inc. | $296k 150,000 shares | +21% | +442% from low-73% from high | |
| 62Notable | Marpai, Inc. | $239k 200,000 shares | - | +291% from low-81% from high |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 29, 2026 | MRAI Marpai, Inc. | AGrant or award Class A Common Stock | +300,000 | $0.00 | $0 | 1,650,000 | Jun 2, 2026 |
| Oct 20, 2025 | MRAI Marpai, Inc. | AGrant or award Class A Common Stock | +550,000 | $0.00 | $0 | 1,350,000 | Oct 22, 2025 |
| Sep 30, 2025 | MRAI Marpai, Inc. | POpen-market purchase Class A Common Stockindirect: See footnote | +147,058 | $1.36 | $200k | 6,419,893 | Oct 2, 2025 |
| Sep 10, 2025 | MRAI Marpai, Inc. | POpen-market purchase Class A Common Stockindirect: See footnote | +896,903 | $1.06 | $950k | 6,272,835 | Sep 26, 2025 |
| Jul 29, 2025 | MRAI Marpai, Inc. | POpen-market purchase Class A Common Stockindirect: See footnote | +371,470 | $1.08 | $400k | 5,375,932 | Aug 1, 2025 |
| Jul 17, 2025 | MRAI Marpai, Inc. | POpen-market purchase Class A Common Stockindirect: See footnote | +86,805 | $1.15 | $100k | 5,004,462 | Jul 21, 2025 |
| Dec 14, 2023 | MRAI Marpai, Inc. | POpen-market purchase Class A Common Stockindirect: See Footnote10b5-1 | +150,000 | $1.97 | $296k | 851,306 | Dec 18, 2023 |
| Nov 21, 2023 | MRAI Marpai, Inc. | POpen-market purchase Class A Common Stock | +200,000 | $1.19 | $239k | 200,000 | Nov 21, 2023 |
Questions about Damien Lamendola
Answered from the filings on this page, as of the latest one.
Is Damien Lamendola buying or selling?
Not in the last 12 months. Damien Lamendola's latest open-market trade on SEC Form 4 was bought $200k of MRAI on Sep 30, 2025.
How did Damien Lamendola's past buys perform?
Measured from the first close after each filing, the stock trailed the S&P 500 by a median 67.8% over six months across 4 past buys, with 0% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does Damien Lamendola file Form 4?
Damien Lamendola has filed Form 4 at MRAI (Marpai, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.